X

Trial Profile

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IDE 161 (Primary)
Indications Advanced breast cancer; Colon cancer; Colorectal cancer; Endometrial cancer; HER2 negative breast cancer; Ovarian cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Sponsors IDEAYA Biosciences

Most Recent Events

28 Oct 2024 Planned number of patients changed from 68 to 216.
28 Oct 2024 Planned End Date changed from 1 Sep 2025 to 1 May 2027.
28 Oct 2024 Planned primary completion date changed from 1 Jun 2025 to 1 Oct 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com